Laurel Wealth Advisors (North Carolina)’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100	Closed	-$1K	–	712
2022 Q1	$1K	Hold	100	–	–	﹤0.01%	656
2021 Q4	$1K	Hold	100	–	–	﹤0.01%	656
2021 Q3	$2K	Hold	100	–	–	﹤0.01%	621
2021 Q2	$2K	Buy	+100	New	+$1.92K	﹤0.01%	699

Other funds holding CDAK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s CDAK Position: Q2 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2022, closing a stake of 100 shares — an estimated $1K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in CDAK in Q2 2021 and held it in 4 quarters. The position peaked at $2K in Q3 2021. 49 funds tracked by Wall St. Rank hold CDAK as of Q2 2022.

Laurel Wealth Advisors (North Carolina) reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 100 Codiak BioSciences, Inc. Common Stock shares in Q2 2022, an estimated $1K.
Laurel Wealth Advisors (North Carolina) first reported a position in Codiak BioSciences, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
Laurel Wealth Advisors (North Carolina)'s Codiak BioSciences, Inc. Common Stock position peaked at $2K in Q3 2021.
49 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q2 2022, filed 12 Aug 2022.